GlaxoSmithKline’s ViiV Healthcare announced positive phase-three trial results for its new HIV drug in a dual-drug regimen, supporting the company’s audacious bet that it can shift the treatment orthodoxy away from three-drug combinations.
from WSJ.com: US Business http://ift.tt/2hDkGOI
via IFTTT
No comments:
Post a Comment